In summary, combining CRT-NPs with anti-CTLA-4 immunotherapy could be a promising approach to improve the effectiveness of immunotherapy in treating certain types of cancer, specifically, those with T-cell-inflamed tumors such as the CT26 colon carcinoma model used in this study. This evidence concerns the gene CTLA4 and colon carcinoma.